Disposition zur neuroleptischen Schwelle

Haase, H J; Kapplinghaus, R.; Ball, P.; Keitel, P.; Koch, C. D.; Mattke, D.; Nöcker, G.; Ritter, R.; Schönbeck, M.; Zahn, M.; Zschucke, C. F.

doi:10.1055/s-0028-1094207

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Simpson & Angus ( 1970) ) includes 12 items for extrapyramidal symptoms arising from psychopharmacological treatment, graded 0 4 . Handwriting test (Haase et al (1968)) is said to demonstrate mild or subclinical extrapyramidal symptoms. Activities of daily living ( A D L performance) were assessed according to a 5 point rating scale (Claesson & MaZm ( 1972) ) (see appendix 3).…”

Section: General Trial Designmentioning

confidence: 99%

A CONTROLLED ONE‐YEAR STUDY OF PIPOTIAZINE PALMITATE AND FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIC SYNDROMES: Evaluation of results at 6 and 12 months' trial

Dencker¹,

Frankenberg²,

Malm³

et al. 1973

Acta Psychiatr Scand

View full text Add to dashboard Cite

Phase 3, maintenance period 2. This period lasted 6 months. As in phase 2, the patients received a monthly dose, which could: however, now be adjusted in amount if desired. Moreover, the monthly assessments were omitted, and the patients were instead assessed 9 and 12 months after the start of the trial.The trial was started in May 1971, and completed in June 1972. Patient selectionAll patients from the department who needed maintenance therapy with neuroleptics and met the following requirements were accepted for the trial:1. Only patients treated with long-acting neuroleptics. 2.The diagnosis should fall within the category of schizophrenic syndromes. Age between 18 and 65 years.4. Duration of disease: > 3 years; hospitalisation: < 10 years. Exclusions:1. Patients with toxicomania (alcoholism or narcomania) . Patientswith symptoms suggesting neurological or other somatic dis-3. Patients treated with high doses (at least 250 mg, single dose) of fluphena-orders. zine enanthate.Sixty-seven patients met the requirements and entered the trial. These 67 patients were matched for sex and age (10 year classes), and distributed randomly between the treatment series. Administration of drugsNo wash-out period was used. The first injection in the present trial was

show abstract

Section: General Trial Designmentioning

confidence: 99%

A CONTROLLED ONE‐YEAR STUDY OF PIPOTIAZINE PALMITATE AND FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIC SYNDROMES: Evaluation of results at 6 and 12 months' trial

Dencker¹,

Frankenberg²,

Malm³

et al. 1973

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Fluspirilene hat sich als wertvolle Ergänzung im Spektrum der Depotneurolepti ka erwiesen. Als erste Substanz mit Depotwirkung nach peroraler Applikation ist in letzter Zeit Penfluridol (R 16 341 -Janssen), ein DiphenylbutylpiperidinDerivat entwickelt und klinisch erprobt worden (Baro et al, 1970;Bonbon et al, 1970;van Praag et al, 1971 ;Tanghe and Vereecken, in press;Haase et al, 1968Haase et al, , 1971.…”

unclassified

Aspekte der neuroleptischen Depottherapie unter besonderer Berücksichtigung klinischer Erfahrungen mit dem peroralen Depotpräparat Penfluridol (R 16 341 — Janssen)

Bruck¹,

Guss²

1974

Int Pharmacopsychiatry

View full text Add to dashboard Cite

Part A discusses in general clinico-pharmacological, pharmacopsychiatric, psychological and social aspects of treatment with long-acting neuroleptics. Previous experiences have confirmed the importance of repository preparations for secondary prevention and their economic value. Part B is a report on an open clinical study of the long-acting agent Penfluridol (R 16 341 - Janssen), perorally administered to 50 patients suffering from schizophrenia. The predominantly antipsychotic substance remains effective for approx. 1 week after application of a single dose ranging from 20 to 120 mg. Apart from extrapyramidal side effects, Penfluridol is well tolerated, no serious incidents were observed.

show abstract

Pharmacogenetic aspects of psychoactive drugs: Facts and fancy

Propping¹,

Kopun²

1973

Hum Genet

View full text Add to dashboard Cite

Disposition zur neuroleptischen Schwelle

Cited by 6 publications

References 0 publications

A CONTROLLED ONE‐YEAR STUDY OF PIPOTIAZINE PALMITATE AND FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIC SYNDROMES: Evaluation of results at 6 and 12 months' trial

A CONTROLLED ONE‐YEAR STUDY OF PIPOTIAZINE PALMITATE AND FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIC SYNDROMES: Evaluation of results at 6 and 12 months' trial

Aspekte der neuroleptischen Depottherapie unter besonderer Berücksichtigung klinischer Erfahrungen mit dem peroralen Depotpräparat Penfluridol (R 16 341 — Janssen)

Pharmacogenetic aspects of psychoactive drugs: Facts and fancy

Contact Info

Product

Resources

About